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CDC Guidance on Antiviral Treatment of Patients with Confirmed, Probable, 
or Suspected Cases of Novel Influenza A (H1N1)
Summary: As a reminder to clinicians, this Health Update summarizes existing CDC guidance issued on May 6, 
2009 on the use of antiviral drugs in novel H1N1 patients and their close contacts. CDC recommends that 
influenza antiviral treatment be given to all hospitalized patients with confirmed, probable, or suspected novel 
influenza A (H1N1) and any patient with confirmed, probable or suspected novel influenza A (H1N1) who is at 
higher risk for seasonal influenza complications. All hospitalized patients should be carefully monitored and 
treated with antiviral medications as soon as possible after admission, including patients who seek treatment 
more than 48 hours after onset of symptoms. The drugs recommended for treatment are either oseltamivir or 
zanamivir. The novel H1N1 viruses are resistant to amantadine and rimantadine.
Background:
Clinical studies indicate that antiviral treatment is safe and effective for seasonal influenza, and that treatment is 
most effective if started as early as possible, preferably within 48 hours of illness onset. Antiviral susceptibility 
testing of novel H1N1 viruses indicates that antiviral drugs should be effective for treatment of this new strain of 
influenza also.
A recent study published in the Morbidity and Mortality Weekly Report (MMWR) described diagnosis, medical 
conditions, and treatment of 30 patients hospitalized in California with novel influenza A (H1N1) infection during 
April and May 2009. The report indicated that only 15 of 30 patients hospitalized with novel H1N1 infection 
received antiviral treatment. Treatment was initiated within 48 hours of symptom onset in only 5 of the 30 patients, 
although in some instances patients presented for medical care more than 48 hours after onset of illness.
Although the majority of hospitalized persons infected with novel influenza A (H1N1) recovered without 
complications, some patients had severe and prolonged illness, and several remain hospitalized. Among 
hospitalized patients with novel influenza A (H1N1), about half of those who had chest x-rays taken had findings 
consistent with pneumonia, but few had evidence of bacterial co-infection. Primary influenza virus pneumonia, 
with or without bacterial co-infection, is a potentially life-threatening illness.
Recommendations:
CDC recommends that antiviral treatment for novel influenza A (H1N1) be given as soon as possible after onset 
of symptoms for all hospitalized patients with confirmed, probable, or suspected novel influenza A (H1N1) virus 
infection. All hospitalized patients with novel influenza A (H1N1) infection should be monitored carefully and 
treated with antiviral therapy, including patients who seek care more than 48 hours after illness onset. Influenza 
antiviral medicines should be initiated as soon as possible if influenza is suspected, and often before diagnostic 
test results (RT-PCR) are available, for maximum benefit. If bacterial co-infection is suspected, antibacterials 
should be directed at likely pathogens (e.g., S. pneumoniae, S. aureus) consistent with existing guidelines for the
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management of community-acquired pneumonia.* Antibacterial therapy also should be initiated after appropriate 
diagnostic specimens are obtained, including blood, respiratory secretions (especially for intubated patients), and 
pleural fluid for culture and urine for pneumococcal antigen testing (in adults).
Patients who are at higher risk for seasonal influenza complications (including people 65 years and older, children 
younger than five years old, pregnant women, and people of any age with chronic medical conditions) are also 
recommended for treatment, regardless of whether they require hospitalization.
For More Information:
Antiviral Treatment for Novel Influenza A (H1N1) Virus Infection 
http://www.cdc.gov/h1n1flu/recommendations.htm
MMWR: Hospitalized Patients with Novel Influenza A (H1N1) Virus Infection --- May 18, 2009 / 58(Early 
Release);1-5 California, April--May, 2009 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58e0518a1.htm
Additional documents for health care providers, public health officials, and the public are available on 
www.cdc.gov. Information for the public is posted daily in both English and Spanish. Also, CDC's toll-free hotline, 
800-CDC-INF0 (800-232-4636) TTY: (888) 232-6348, is available 24 hours a day, every day.
*Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America / American Thoracic 
Society Consensus Guidelines on the Management of Community-acquired Pneumonia in Adults. Clin Infect Dis 
2007;44 Suppl 2:S27-72.
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